Home
Screener
Insiders
Rankings
Sign in
Create account
Insiders
· Profile
Smith Jason Drew
General Counsel at UroGen Pharma. Filing since 17 May 2021.
CIK 0001821479
Company
Date
Role
Action
Shares
Amount
Of holding
URGN
UroGen Pharma Ltd.
8 Sep 2026
General Counsel
Sold at will
1,519
$64.62K
2.8%
URGN
UroGen Pharma Ltd.
3 Feb 2026
General Counsel
Sold at will
7,479
$147.26K
12.7%
URGN
UroGen Pharma Ltd.
8 Sep 2025
General Counsel
Sold at will
1,520
$29.05K
3.4%
URGN
UroGen Pharma Ltd.
28 Jul 2025
General Counsel
Sold at will
7,522
$143.97K
15.3%
URGN
UroGen Pharma Ltd.
31 Jan 2025
General Counsel
Sold at will
7,379
$82.20K
21.8%
URGN
UroGen Pharma Ltd.
9 Sep 2024
General Counsel
Sold at will
1,521
$19.89K
5.7%
URGN
UroGen Pharma Ltd.
31 Jan 2024
General Counsel
Sold at will
4,993
$78.59K
21.0%
URGN
UroGen Pharma Ltd.
31 Aug 2023
General Counsel
Sold at will
3,800
$68.44K
17.1%
URGN
UroGen Pharma Ltd.
31 Jan 2023
General Counsel
Sold, plan not stated
1,636
$16.56K
11.5%
URGN
UroGen Pharma Ltd.
31 Aug 2022
General Counsel
Sold, plan not stated
3,606
$26.00K
22.8%
URGN
UroGen Pharma Ltd.
31 Jan 2022
General Counsel
Sold, plan not stated
414
$3.14K
5.3%
URGN
UroGen Pharma Ltd.
30 Nov 2021
General Counsel
Sold, plan not stated
3,803
$45.75K
35.1%
URGN
UroGen Pharma Ltd.
17 May 2021
General Counsel
Bought
2,500
$39.28K
opened
13 decisions on file.
